Polaryx Therapeutics, Inc. PLYX 深 沪
等待开盘 06-25 09:30:00 美东时间
2.40
-0.010
-0.41%
华盛通- 最 高2.52
- 今 开2.52
- 成交量 3.90万股
- 最 低 2.34
- 昨 收 2.41
- 总市值 1.14亿
- 52周最高 48.91
- 市盈率 静 --
- 换手率 0.08%
- 52周最低 2.01
- 委 比 -99.43%
- 总股本 4734.33万
- 历史最高 48.91
- 量 比 0.51
- 振 幅 7.47%
- 历史最低 2.01
- 每 手 1
- 风险率 5.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Friday's After-Market Session
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 33.0% to $2.5 during F...
05-30 05:05
Polaryx Therapeutics shares are trading higher after the company announced closing of a $10 million private investment in public equity financing.
Polaryx Therapeutics shares are trading higher after the company announced clos...
05-28 23:24
Why Polaryx Therapeutics Stock Is Surging On Thursday?
Polaryx Therapeutics (NASDAQ: PLYX) stock climbs on Thursday following a $10M private placement to launch its Phase 2 SOTERIA trial for rare lysosomal storage disorders.
05-28 22:45
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers BioLine Rx (NASDAQ:BLRX) stock increased by 12.5% to $3.11 during Mond...
05-19 05:05
Polaryx Therapeutics Says FDA Grants Fast Track Designation To PLX-200 For Treatment Of JNCL/CLN3 Disease, Krabbe Disease, And Sandhoff Disease
Polaryx Therapeutics, Inc. (NASDAQ:PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs, today announced that the U.S. Food and Drug Administration (FDA) has
04-21 20:37
Polaryx Therapeutics Says FDA Grants Fast Track Designation To PLX-200 For Treatment Of Late-Infantile Neuronal Ceroid Lipofuscinosis
Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX‑200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc.
03-17 20:33
美股牛股 | VYGR飙升21%，Q4亏损收窄及销售额超预期；Figure大涨超20%
VYGR飙升21%，Q4亏损收窄及销售额超预期；Figure大涨超20%，进军汽车贷款市场获华尔街唱多；Stagwell涨逾17%，引入AppLovin先进的移动广告平台>>
03-11 16:04
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
Maxim Group Initiates Coverage On Polaryx Therapeutics with Buy Rating, Announces Price Target of $10
Maxim Group analyst Jason McCarthy initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and announces Price Target of $10.
02-28 05:28
What's Going On With Polaryx Therapeutics Stock Wednesday?
Polaryx Therapeutics Inc. (NASDAQ: PLYX) stock fell after a surge due to a major clinical development announcement.
02-18 23:19
